Biotech Archives - Page 74 of 795

2 minute read

BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity Of Bria-OTS+ And Bria-PROS+ Clinical Candidates For Breast And Prostate Cancer

April 10, 8:10 AM

Preclinical data shows that BriaCell's Bria-OTS+™ and Bria-PROS+™ effectively induce an anti-cancer immune response via multiple mechanisms including naïve helper and killer T cells, dendritic cells, and

BCTX

3 minute read

ProPhase Labs Seeks To Transform Esophageal Cancer Detection And Management With Launch Of Its BE-Smart Test In H2 2024

By Benzinga Newsdesk

April 10, 8:09 AM

ProPhase Labs, Inc. (NASDAQ:PRPH) ("ProPhase" or the "Company"), a next-generation biotech, genomics, and diagnostics company, today reported its progress on the commercialization of its breakthrough BE-Smart test for

PRPH

3 minute read

Acrivon Therapeutics Presents Data At AACR Annual Meeting Highlighting Capabilities Of Acrivon Predictive Precision Proteomics For The Discovery Of ACR-2316, A Novel, Selective WEE1/PKMYT1 Inhibitor, And The Identification Of Actionable Resistance Mech…

By Benzinga Newsdesk

April 10, 8:07 AM

ACR-2316, which was internally discovered using biological SAR enabled by AP3 to overcome limitations of benchmark clinical WEE1 and PKMYT1 inhibitors, demonstrates potent anticancer activity in preclinical studies and

ACRV

2 minute read

Qualigen Therapeutics’ Novel Direct Pan-RAS Inhibitors Presented At American Association Of Cancer Research 2024 Annual Meeting

By Benzinga Newsdesk

April 10, 8:06 AM

Poster Includes Preclinical Data on Novel Direct Pan-RAS InhibitorsCARLSBAD, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (("Qualigen" or "the Company, NASDAQ:QLGN) today announces a poster

QLGN

2 minute read

EXCLUSIVE: Adial Pharmaceuticals’ Potential Treatment For Alcohol Use Disorder Shows Encouraging Safety, Patient Compliance

By Vandana Singh

April 10, 8:00 AM

Adial Pharmaceuticals releases a peer-reviewed article on AD04, its lead investigational drug for Alcohol Use Disorder. The study highlights a strong safety profile & liver safety compared to a placebo.

ADIL

2 minute read

Chinese Biotech YS Biopharma’s Next-Gen Rabies Vaccine Non-Inferior To Approved Competitor

By Vandana Singh

April 9, 3:30 PM

YS Biopharma unveils interim results from Phase 3 trial of PIKA Rabies Vaccine, meeting primary endpoints. With accelerated immunity in 7 days, it could revolutionize rabies prevention.

2 minute read

Enliven Therapeutics Well-Positioned, With Conservative Trading Levels-Analyst Says

By Vandana Singh

April 9, 2:26 PM

Mizuho Securities initiates coverage on Enliven Therapeutics. Expectations high for late 2024 Phase 1 results. Enliven poised to revolutionize CML treatment, addressing current TKI limitations. Mizuho bullish with Buy rating, $34 price target. ELVN's trading value suggests conservative estimation compared to CML market potential.

ELVN

2 minute read

Alkermes’ Sleeping Disorder Studies’ Data Look Excellent, Analyst Says

By Vandana Singh

April 9, 2:23 PM

ALKS 2680 reports positive results in narcolepsy & idiopathic hypersomnia study. Statistically significant improvements in sleep latency were observed across all doses tested. Phase 2 study for NT2 patients is planned for 2nd half of 2024. Jefferies raises price target & probability of success for ALKS-2680.

ALKS

1 minute read

Why Is Moderna Stock Trading Higher On Tuesday?

By Vandana Singh

April 9, 2:16 PM

Moderna stock jumps post AACR 2024 presentation of mRNA-4157 + Keytruda data in advanced HPV-negative head and neck carcinoma. Positive responses in the Phase 1 trial, with a 27.3% objective response rate and 63.6% disease control rate. Promising results and ongoing trials.

MRK

2 minute read

Pfizer Seeks Expanded Use Of Abrysvo As Vaccine Shows Potential In 18+ Patients

By Vandana Singh

April 9, 12:20 PM

Discover pivotal Phase 3 trial results for Pfizer's Abrysvo vaccine in adults 18-59 at risk of severe RSV disease. Achieved immunogenicity and safety milestones pave the way for potential regulatory approval, addressing a critical unmet need.

PFE